Last reviewed · How we verify
Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation
This clinical trial aims to find a better drug concentration of Remifentanil in Uterine Fibroid Ablation. The main question it seeks to answer is: \[primary hypothesis 1\] Remifentanil concentration of 2.0 ng/mL provides better pain control in Uterine Fibroid Ablation. There is a comparison group in this study: Researchers will compare Remifentanil concentration of 1.0 ng/mL to see if provides similar pain control with fewer side effects. Participants will be separated into two groups, one group with a Remifentanil concentration of 2.0 ng/mL and the other 1.0 ng/mL. During uterine fibroid ablation, the patient\'s pain index will be recorded (using a Visual Analogue Scale (VAS) of 0\~10 points). We will also record vital signs during the procedure.
Details
| Lead sponsor | Kaohsiung Medical University |
|---|---|
| Phase | PHASE4 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 60 |
| Start date | Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Oct 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Uterine Fibroids (UF)
Interventions
- arm 2
- arm 1